Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 101–200 of 1,000
Why did p53 gene therapy fail in ovarian cancer?
Zeimet, A. G., & Marth, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01139-2 · Cited by 199
p53 Signaling and Cell Cycle Checkpoints
Stewart, Z. A., & Pietenpol, J. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000199t · Cited by 202
5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction
Sun, X.-X., Dai, M.-S., & Lu, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610621200 · Cited by 199
Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review
Mohajeri, M., & Sahebkar, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.005 · Cited by 195
LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers
Yu, H., Yue, X., Zhao, Y., Li, X., Wu, L., Zhang, C., Liu, Z., Lin, K., Xu-Monette, Z. Y., Young, K. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6218 · Cited by 192
Montaner, B., Navarro, S., Piqué, M., Vilaseca, M., Martinell, M., Giralt, E., Gil, J., & Pérez‐Tomás, R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703614 · Cited by 192
“As prodigiosin-induced apoptosis is p53-independent, this could mean an advantage over other chemotherapeutic drugs (Brown & Wouters, 1999; Bunz et al., 1999).”
BackgroundGenome changes and gene expression in human solid tumors
Gray, J. W., & Collins, C. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.443 · Cited by 193
Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis
Bernal, J. A., Luna, R., Espina, Á., Lázaro, I., Ramos-Morales, F., Romero, F., Arias, C., Silva, A., Tortolero, M., & Pintor-Toro, J. A. (2002) · Nature Genetics · doi:10.1038/ng997 · Cited by 193
Mechanisms of doxorubicin resistance in hepatocellular carcinoma
Cox, J., & Weinman, S. (2016) · Hepatic Oncology · doi:10.2217/hep.15.41 · Cited by 187
Functional interactions and signaling properties of mammalian DNA mismatch repair proteins
Bellacosa, A. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400948 · Cited by 189
“control of cell cycle checkpoints and regulation of apoptosis.(110) Thus, it is possible that Ser-15/ Ser-392 phosphorylation and stabilization of p53 in”
BackgroundWeber, T., Lu, M., Anděra, L., Lahm, H., Gellert, N., Fariss, M. W., Kořínek, V., Sattler, W., Ucker, D. S., Terman, A., et al. (2002) · PubMed · Cited by 203
Centrosome number is controlled by a centrosome-intrinsic block to reduplication
Wong, C., & Stearns, T. (2003) · Nature Cell Biology · doi:10.1038/ncb993 · Cited by 185
“Therefore, we compared the kinetics of centrosome reduplication in primary HDF cells, HCT116 p53 +/+ colon cancer cells and HCT116 p53 −/− cells generated by somatic knockout of the p53 gen”
MethodOverview of Tumor Cell Chemoresistance Mechanisms
Gatti, L., & Zunino, F. (2005) · Chemosensitivity · doi:10.1385/1-59259-889-7:127 · Cited by 179
Apoptosis and colorectal cancer
Watson, A. J. M. (2004) · Gut · doi:10.1136/gut.2004.052704 · Cited by 177
Single nucleotide polymorphism seeking long term association with complex disease
Kirk, B. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf466 · Cited by 179
Yoshida, Y., Izumi, H., Torigoe, T., Ishiguchi, H., Itoh, H., Kang, D., & Kohno, K. (2003) · PubMed · Cited by 210
Karpf, A. R., Moore, B. C., Ririe, T. O., & Jones, D. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09243-5 · Cited by 176
“This observation is consistent with a role for p53 activation in 5-aza-CdR-mediated cytotoxicity, in that p21 disruption is known to shift p53 dependent responses from growth arrest to apoptosis (Bunz et al., 1999; Tian et al., 2000).”
Bykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 172
“Of these agents, cisplatin (22) and 5-fluorouracil ( 8 ) have been shown to preferentially affect cells carrying wild-type p53.”
BackgroundPrognostic Values of microRNAs in Colorectal Cancer
Xi, Y., Formentini, A., Chien, M., Weir, D. B., Russo, J. J., Ju, J., Kornmann, M., & Ju, J. (2006) · Biomarker Insights · doi:10.1177/117727190600100009 · Cited by 173
Allegra, C. J., Parr, A. L., Wold, L. E., Mahoney, M. R., Sargent, D. J., Johnston, P., Klein, P., Behan, K., O’Connell, M. J., Levitt, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.080 · Cited by 170
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
Longley, D. B., Allen, W. L., & Johnston, P. G. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.001 · Cited by 171
Chemoresistance in solid tumours
Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl280 · Cited by 170
“For example, loss of p53 function has been correlated with decreased sensitivity to 5-FU in vitro [92, 93].”
BackgroundAbdel-Rahman, W. M., Katsura, K., Rens, W., Gorman, P. A., Sheer, D., Bicknell, D., Bodmer, W. F., Arends, M. J., Wyllie, A. H., & Edwards, P. A. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041603298 · Cited by 171
Bertheau, P., Turpin, E., Rickman, D. S., Espié, M., de Reyniès, A., Feugeas, J.-P., Plassa, L.-F., Soliman, H., Varna, M., de Roquancourt, A., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040090 · Cited by 173
“In contrast, TP53-mutant cells that cannot arrest in the cell cycle would subsequently progress towards mitotic catastrophe [10,37].”
BackgroundMechanism of Apoptosis Induced by Curcumin in Colorectal Cancer
Ismail, N. I., Othman, I., Abas, F., H. Lajis, N., & Naidu, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102454 · Cited by 166
“Cell and tumor types, cellular microenvironment and intracellular signals may have some influences in the p53 activation or p53 aberration outcome [317,320].”
Backgroundp53 and disease: when the guardian angel fails
Royds, J. A., & Iacopetta, B. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401913 · Cited by 168
Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents
Nitta, M., Kobayashi, O., Honda, S., Hirota, T., Kuninaka, S., Marumoto, T., Ushio, Y., & Saya, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207873 · Cited by 167
“Consistent with previous observations (Bunz et al., 1998, 1999), we have shown that p53 plays a critical role in maintenance of G2 checkpoint and in prevention of mitotic death in response to DNA damage occurring between S and G2 phases.”
BackgroundResultATM activates p53 by regulating MDM2 oligomerization and E3 processivity
Cheng, Q., Chen, L., Li, Z., Lane, W. S., & Chen, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.294 · Cited by 165
“The samples were boiled and fractionated on SDS–PAGE and subjected to western blot analysis using MDM2 and MDMX phosphorylation-specific antibodies.”
MethodResultThe role of DNA damage responses in p53 biology
Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 160
“This can be seen in fibroblasts receiving high-dose gamma irradiation or the abovementioned HCT116 cells after treatment with adriamycin (Bunz et al. 1999; Speidel et al. 2006).”
BackgroundGene expression alterations in doxorubicin resistant MCF7 breast cancer cell line
AbuHammad, S., & Zihlif, M. (2013) · Genomics · doi:10.1016/j.ygeno.2012.11.009 · Cited by 164
“[38] found that expression of p21 protects cells from doxorubicin-induced apoptosis.”
BackgroundTriptolide and Chemotherapy Cooperate in Tumor Cell Apoptosis
Chang, W.-T., Kang, J. J., Lee, K.-Y., Wei, K., Anderson, E., Gotmare, S., Ross, J. A., & Rosen, G. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009713200 · Cited by 164
Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh, A., Toyota, M., Itoh, F., Sasaki, Y., Suzuki, H., Ogi, K., Kikuchi, T., Mita, H., Yamashita, T., Kojima, T., et al. (2003) · PubMed · Cited by 163
The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage
Wang, P., Yu, J., & Zhang, L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700020104 · Cited by 163
Moos, P. J., Edes, K., Cassidy, P., Massuda, E., & Fitzpatrick, F. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211134200 · Cited by 163
Mahyar-Roemer, M., Katsen, A., Mestres, P., & Roemer, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1516 · Cited by 163
p53 Regulation of G 2 Checkpoint Is Retinoblastoma Protein Dependent
Flatt, P. M., Tang, L. J., Scatena, C. D., Szak, S. T., & Pietenpol, J. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.12.4210-4223.2000 · Cited by 161
“Several preclinical studies have correlated loss of specific cell cycle regulatory gene products with enhanced vulnerability to anticancer agents (6, 19, 51, 55).”
BackgroundMahyar-Roemer, M., & Roemer, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204440 · Cited by 162
“…by demonstrating that a defective p21 response can lead HCT116 cells exposed to DNA damaging drugs or radiation to undergo illegitimate DNA replication and to ultimately su er apoptotic death instead of a transient cell cycle arrest (Waldman et al., 1996; Bunz et al., 1999; Polyak et al., 1996).”
BackgroundMethodInfluentialDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
“Given that MYC upregulates DR5 levels via an indirect mechanism (Figure 4C), we sought to determine if MYC’s effects required functional p53 by utilizing a derivative of HCT116 in which both p53 alleles have been knocked out by homologous recombination (HCT116 p53 / ; Bunz et al., 1999).”
BackgroundActivation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA
Kim, J.-S., Lee, C., Bonifant, C. L., Ressom, H., & Waldman, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00537-06 · Cited by 161
“These include both extracellular insults—radiation, DNAdamaging chemotherapeutics, spindle poisons, antimetabolites, and oxygen deprivation—and intracellular stimuli—oncogene activation, cellular aging, and oxygen radical formation (1, 7 , 10, 16, 17, 23, 52).”
BackgroundSelf-citationCircadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor
Granda, T. G., Liu, X.-H., Smaaland, R., Cermakian, N., Filipski, E., Sassone-Corsi, P., & Lévi, F. (2005) · The FASEB Journal · doi:10.1096/fj.04-2665fje · Cited by 161
Li, X. L., Subramanian, M., Jones, M. F., Chaudhary, R., Singh, D. K., Zong, X., Gryder, B., Sindri, S., Mo, M., Schetter, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.041 · Cited by 160
“In contrast, upon p53 knockdown, PURPL-WT cells were more sensitive to DOXO (Figure S8C) consistent with literature (Bunz et al., 1999) where HCT116 were shown to be more sensitive to DOXO after p53 deletion.”
ResultLi, H., Rokavec, M., Jiang, L., Horst, D. A., & Hermeking, H. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.017 · Cited by 166
Exploiting cancer cell cycling for selective protection of normal cells.
Blagosklonny, M. V., & Pardee, A. B. (2001) · PubMed · Cited by 199
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Self-citationGeisler, S. B., Børresen‐Dale, A., Johnsen, H., Aas, T., Geisler, J., Akslen, L. A., Anker, G. B., & Lønning, P. E. (2003) · PubMed · Cited by 168
Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53
Satapathy, S. R., Mohapatra, P., Preet, R., Das, D., Sarkar, B., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.176 · Cited by 151
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells
Kim, E. L., Wuestenberg, R., Rübsam, A., Schmitz-Salue, C., Warnecke, G., Bucker, E.-M., Pettkus, N., Speidel, D., Rohde, V., Schulz‐Schaeffer, W., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop046 · Cited by 166
“This lack of correlation between chloroquine-induced stabilization of p53 and its phosphorylation at Ser15 was observed not only in glioma cells but also in the different cellular context of an HCT116 colon carcinoma cell line, a widely used experimental paradigm of the p53 pathway.(40) Similar to the pattern observed…”
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520001 · Cited by 148
Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells
Jiang, M., & Milner, J. (2003) · Genes & Development · doi:10.1101/gad.252603 · Cited by 165
“Selective silencing of Bcl-2 expression Initially we used paired isogenic clones of HCT116 p53+/+ and p53−/− cells (Bunz et al. 1999; Zhang et al. 2000), and to silence Bcl-2 expression we selected two Bcl-2 mRNA target sequences (Fig.”
BackgroundMethod5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation
Zhu, W., Hileman, T., Ke, Y., Wang, P., Lu, S., Duan, W., Dai, Z., Tong, T., Villalona-Calero, M. A., Plass, C., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311703200 · Cited by 158
P53: An ubiquitous target of anticancer drugs
Blagosklonny, M. V. (2002) · International Journal of Cancer · doi:10.1002/ijc.10158 · Cited by 146
Balan, K. V., Prince, J. S., Han, Z., DIMAS, K. S., Hadzopoulou‐Cladaras, M., Wyche, J. H., Sitaras, N. M., & Pantazis, P. (2006) · Phytomedicine · doi:10.1016/j.phymed.2006.03.009 · Cited by 174
Baptiste, N., Friedlander, P. A., Chen, X., & Prives, C. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205015 · Cited by 168
“It is interesting that Bunz et al. (1999) found that the ability of 5-FU to kill cultured colon cancer HCT116 cells in a p53-dependent manner involves speci®cally the impairment of RNA metabolism by this analogue, rather than its e ect on DNAmetabolism or thymidylate synthetase.”
BackgroundResulthTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Massard, C., Zermati, Y., Pauleau, A.-L., Larochette, N., Métivier, D., Sabatier, L., Kroemer, G., & Soria, J.-C. (2006) · Oncogene · doi:10.1038/sj.onc.1209487 · Cited by 144
“Wild-type, p53 knockout (Bunz et al., 1999) and Bax knockout HCT116 cells (Zhang et al., 2000) were cultured in the same conditions, with the only difference that DMEM was replaced by McCoy’s 5A medium.”
MethodRescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva, N., Friedler, A., Bozko, P., Wiman, K. G., Fersht, A. R., & Selivanova, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835733100 · Cited by 118
Shared pathways: Death receptors and cytotoxic drugs in cancer therapy
Peták, I., & Houghton, J. A. (2001) · Pathology & Oncology Research · doi:10.1007/bf03032574 · Cited by 157
MDMX regulation of p53 response to ribosomal stress
Gilkes, D. M., Chen, L., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601424 · Cited by 142
“MDMX expression was induced with 0.1–1 mg/ml tetracycline.”
MethodInfluentialp53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis
Kho, P. S., Wang, Z., Zhuang, L., Li, Y., Chew, J.-L., Ng, H.-H., Liu, E. T., & Yu, Q. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311912200 · Cited by 143
Tai, I. T., Dai, M., Owen, D. A., & Chen, L. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23002 · Cited by 142
DNA damage induces two distinct modes of cell death in ovarian carcinomas
Vakifahmetoglu, H., Olsson, M., Tamm, C., Heidari, N., Orrenius, S., & Zhivotovsky, B. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402286 · Cited by 157
“Previously, it has been shown that p53 plays a critical role in the maintenance of the G2 checkpoint and in the prevention of premature entrance into mitosis after DNA damage.(4,21) Moreover, failure of cells to arrest in the G2 phase in response to cytotoxic agents has been described as a consequence of the absence,…”
BackgroundXavier, C. P. R., Lima, C. F., Rohde, M., & Pereira‐Wilson, C. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1641-9 · Cited by 142
“37 Previous studies have shown that, independently of MSI status, mutations in the gene 38 P53 contribute to 5-FU resistance in CRC and have profound effects on drug responses 39 [12,13] with reduced induction of apoptosis and inhibition of cell cycle [14,15].”
BackgroundApoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase
Salomon, A. R., Voehringer, D. W., Herzenberg, L. A., & Khosla, C. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00057-0 · Cited by 140
“lines, developed by Vogelstein and coworkers [7,8].”
BackgroundProspective therapeutic applications of p53 inhibitors
Gudkov, A. V., & Komarova, E. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.153 · Cited by 155
TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Gokgoz, N., Parkes, R., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.074 · Cited by 141
High resolution melting for mutation scanning of TP53exons 5–8
Krypuy, M., Ahmed, A. A., Etemadmoghadam, D., Hyland, S. J., Chenevix‐Trench, G., DeFazio, A., Fox, S. B., Brenton, J. D., Bowtell, D. D. L., & Dobrovic, A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-168 · Cited by 153
“There are a variety of stresses that have been shown to activate p53 including DNA damage, cell-cycle aberrations, hypoxia, and aberrant growth signals resulting from expression of oncogenes [5-10].”
BackgroundCrea, F., Nobili, S., Paolicchi, E., Perrone, G., Napoli, C., Landini, I., Danesi, R., & Mini, E. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.001 · Cited by 137
The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 153
“[124], El-Deiry [125], and Dahm-Daphi [126]) With conflicting data in vitro, it is difficult to translate experimental observations based on cell lines to scenarios relevant to human cancers irradiated in situ.”
BackgroundBailey, S. N., Sabatini, D. M., & Stockwell, B. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404425101 · Cited by 146
Targeting p53 for enhanced radio- and chemo-sensitivity
Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 151
“Loss of p53 has been shown to confer resistance to 5-fluorouracil and changes in RNA metabolism seem to initiate events culminating in the expression of p53 [53, 54].”
BackgroundTan, J. Y., Zhuang, L., Leong, H. S., Iyer, N. G., Liu, E. T., & Yu, Q. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1226 · Cited by 139
“In human colorectal cancer HCT116 cells, p53 activation by DNA-damaging agent Adriamycin and DNA analogue 5-FU results in cell cycle arrest and apoptosis, respectively (26).”
BackgroundMethylation and colorectal cancer
Jubb, A. M., Bell, S. M., & Quirke, P. (2001) · The Journal of Pathology · doi:10.1002/path.923 · Cited by 142
“Likewise, a publication from the Johns Hopkins group found that p53 disruption rendered cells strikingly resistant to the effects of the 5-FU anti-metabolite [226].”
BackgroundYang, C., Song, J., Hwang, S., Choi, J., Song, G., & Lim, W. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102144 · Cited by 135
Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival
Tonnessen-Murray, C. A., Frey, W. D., Rao, S. G., Shahbandi, A., Ungerleider, N. A., Olayiwola, J. O., Murray, L. B., Vinson, B. T., Chrisey, D. B., Lord, C. J., et al. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201904051 · Cited by 127
“TP53 mutant cells are more sensitive to DNA damage (Brown and Wouters, 1999; Bunz et al., 1999), but cells that survive can undergo p53-independent senescence in culture (Chang et al.”
BackgroundYamaguchi, H., Chen, J., Bhalla, K., & Wang, H.-G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401530200 · Cited by 129
Ravi, R. K., & Bedi, A. (2002) · PubMed · Cited by 145
FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression
Varghese, V., Magnani, L., Harada-Shoji, N., Mauri, F., Szydlo, R. M., Yao, S., Lam, E. W.-F., & Kenny, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-018-38017-0 · Cited by 130
JNK2-dependent regulation of SIRT1 protein stability
Ford, J., Ahmed, S., Allison, S., Jiang, M., & Milner, J. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6799 · Cited by 127
Identification of Genes That Mediate Sensitivity to Cisplatin
Niedner, H., Christen, R. D., Lin, X., Kondo, A., & Howell, S. B. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1153 · Cited by 126
Smith, F. M., Reynolds, J. V., Miller, N., Stephens, R. B., & Kennedy, M. J. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.09.010 · Cited by 125
Drug resistance in lung cancer
Ramesh, R. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s6861 · Cited by 142
“Numerous investigators have reported that inactivation or loss of p53 function can lead to resistance to drugs such as 5-fluorouracil and cisplatin.(110,111) Moreover, most cancer patients with p53 mutations initially respond to chemotherapy but gradually develop resistance to the drugs as the result of a mutation in,…”
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
Panczyk, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9775 · Cited by 122
Siddiqui, R. A., Harvey, K. A., Xu, Z., Bammerlin, E., Walker, C. L., & Altenburg, J. D. (2011) · BioFactors · doi:10.1002/biof.181 · Cited by 126
“Other studies suggest that the efficacy of 5-FU is often related to the p53 status of human colon cancer cells [56].”
BackgroundSohn, D., Essmann, F., Schulze-Osthoff, K., & Jänicke, R. U. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1569 · Cited by 118
“In addition, wild-type HCT116 cells were efficiently chemosensitized and radiosensitized by either homologous disruption of the p21 gene or by p21 antisense oligonucleotides both in vitro and in tumor xenografts in nude mice ( 10 , 11).”
Mullally, J. E., Moos, P. J., Edes, K., & Fitzpatrick, F. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102198200 · Cited by 118
de la Cruz-Morcillo, M. A., Valero, M. L. L., Callejas-Valera, J. L., Arias-González, L., Melgar-Rojas, P., Galán-Moya, E. M., García-Gil, E., García-Cano, J., & Sánchez-Prieto, R. (2012) · Oncogene · doi:10.1038/onc.2011.321 · Cited by 117
“Cells lacking p53 showed a marked resistance to 5-FU (Figure 4b) and an absence of apoptosis (Figures 4d and e), supporting previous observations (Bunz et al., 1999).”
InfluentialRetractedPG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.
Fidler, J. M., Li, K., Chung, C. T., Wei, K., Ross, J. A., Gao, M., & Rosen, G. (2003) · PubMed · Cited by 129
Gmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 131
Avery-Kiejda, K. A., Bowden, N. A., Croft, A. J., Scurr, L. L., Kairupan, C. F., Ashton, K. A., Talseth-Palmer, B. A., Rizos, H., Zhang, X. D., Scott, R. J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-203 · Cited by 113
“Furthermore, there have been reports demonstrating that cells lacking functional P53 were more susceptible to cell death induced by DNA-damaging agents [45-51].”
BackgroundApoptotic pathways as a therapeutic target for colorectal cancer treatment
Abraha, A. M., & Ketema, E. B. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i8.583 · Cited by 124
Mechanisms of regulatory diversity within the p53 transcriptional network
Espinosa, J. M. (2008) · Oncogene · doi:10.1038/onc.2008.37 · Cited by 129
“…early on by the Vogelstein lab when showing that, whereas p53 protects colon carcinoma cells from the apoptotic effects of the drug doxorubicin by enforcing a cell cycle arrest response, it mediates the apoptotic effects of the drug 5-fluorouracil (5-FU) in the same cell types (Bunz et al., 1999).”
BackgroundMolecular mechanisms of platinum resistance: still searching for the Achilles? heel
Wernyj, R. P., & Morin, P. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.08.002 · Cited by 129
TR3/Nur77 in colon cancer cell apoptosis.
Wilson, A. J., Arango, D., Mariadason, J. M., Heerdt, B. G., & Augenlicht, L. H. (2003) · PubMed · Cited by 131
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 108
“The underlying mechanism of resistance in p53-depleted colon cancer cells might be due to a lack of ability to bind apoptosis inducing signaling molecules and, hence, malignant cells are protected from cell death (Figure 1) [56].”
BackgroundCarvallo, F. R., Trejo‐Solís, C., Gómez-Ruíz, C., Rodríguez-Aguilera, E., Macías‐Rosales, L., Barberena, E. C., Cedillo-Peláez, C., Gracia‐Mora, I., Ruíz-Azuara, L., Madrid‐Marina, V., et al. (2007) · BioMetals · doi:10.1007/s10534-007-9089-4 · Cited by 116
“It is known that cancerous cells with inactive p53 are resistant to apoptosis inducing drugs mediated by the mitochondria (Bunz et al. 1999), so the search of new drugs with antineoplastic activity is a reasonable quest; our findings postulate Cas III-ia is a potential candidate for the therapy of…”
BackgroundNear-Infrared-Triggered Anticancer Drug Release from Upconverting Nanoparticles
Fedoryshin, L. L., Tavares, A. J., Petryayeva, E., Doughan, S., & Krull, U. J. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am503039f · Cited by 117
Regulation of p53 Stability and Function in HCT116 Colon Cancer Cells
Kaeser, M. D., Pebernard, S., & Iggo, R. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311732200 · Cited by 112
Blagosklonny, M. V., Robey, R., Bates, S., & Fojo, T. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8625 · Cited by 112
“In human cancer cells, the relationship between loss of p53 and drug sensitivity is more complex (14), but inactivation of p53 often correlates with resistance to DNA-damaging drugs (15–17).”
BackgroundJavelaud, D., & Besançon, F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204497200 · Cited by 135
Prast‐Nielsen, S., Cebula, M., Pader, I., & Arnér, E. S. J. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.008 · Cited by 119
“HCT116 (colorectal carcinoma) wild-type and p53−/− cells [55] were kindly provided by Dr.”
Method
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.